A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases.

[1]  V. Combaret,et al.  Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients. , 1989, Cancer treatment reviews.

[2]  T. Eberlein,et al.  Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. , 1988, Cancer research.

[3]  S. Litwin,et al.  A phase I study of recombinant interleukin 2 plus recombinant beta-interferon. , 1988, Cancer research.

[4]  H. Heslop,et al.  In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation. , 1988, Journal of immunology.

[5]  R. Bechhofer,et al.  Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. , 1988, Cancer research.

[6]  H. Drexler,et al.  Interleukin 2 enhances cytotoxic cell function in vitro after T‐cell depleted marrow transplantation , 1987, British journal of haematology.

[7]  M. Link,et al.  ABSENCE OF CELL SURFACE LFA-1 AS A MECHANISM OF ESCAPE FROM IMMUNOSURVEILLANCE , 1987, The Lancet.

[8]  N. Berger,et al.  Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Thompson,et al.  Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. , 1987, Cancer research.

[10]  S. Steinberg,et al.  Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. , 1987, Annals of internal medicine.

[11]  G. Marshall,et al.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. , 1987, The New England journal of medicine.

[12]  J. Zucker,et al.  High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Rosenberg,et al.  Clinical effects and toxicity of interleukin‐2 in patients with cancer , 1986, Cancer.

[14]  S. Rosenberg,et al.  Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo. , 1986, Journal of immunological methods.

[15]  Michael Loran Dustin,et al.  Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). , 1986, Journal of immunology.

[16]  C. Rooney,et al.  Natural killer cell activity following T‐cell depleted allogeneic bone marrow transplantation , 1986, British journal of haematology.

[17]  K. Anderson,et al.  Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. , 1986, Blood.

[18]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[19]  R. Mertelsmann,et al.  Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. , 1984, Blood.

[20]  F. Sánchez‐Madrid,et al.  The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. , 1983, Journal of immunology.

[21]  P. Biron,et al.  Very long delay to engraftment after ABMT in neuroblastoma patients and effect of CD8 monoclonal antibody in vivo therapy. , 1988, Progress in clinical and biological research.

[22]  J. Zucker,et al.  Definition of response and remission in children over one year of age with advanced neuroblastoma: proposition for a scoring system. , 1987, Pediatric hematology and oncology.

[23]  M. López-Botet,et al.  Defective interleukin 2 receptor expression is associated with the T cell disfunction subsequent to bone marrow transplantation , 1987, European journal of immunology.

[24]  S. Carrel,et al.  Recombinant interferon‐γ can induce the expression of HLA‐DR and ‐DC on DR‐negative melanoma cells and enhance the expression of HLA‐ABC and tumor‐associated antigens , 1985 .